ArticleCardiovascular diabetology2022
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
Article in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials.Acta diabetologica · 2025Pooled it
- Pooled it
- Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.Journal of nephrology · 2024Pooled it
- CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.Cardiovascular diabetology · 2026Article
- Chemical Constituents, Pharmacological Activities, and Cardiovascular Protective Mechanisms ofInternational journal of molecular sciences · 2026Review
- Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.Therapeutic advances in endocrinology and metabolism · 2026Review
- CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.Cardiovascular diabetology · 2025Article
- CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.Cardiovascular diabetology · 2024Article
- CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.Cardiovascular diabetology · 2023Article
- From New Endocrine Entities Requiring New Approaches to New Approaches Leading to New Endocrine Entities.Diagnostics (Basel, Switzerland) · 2023Article
- Novel Strategies for the Treatment of COVID-19.Drugs in R&D · 2022Article
- Tirzepatide: A Systematic Update.International journal of molecular sciences · 2022 · on this mapReview
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 13 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18-19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year's focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1-5, and STEP 1-5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10-11, 2022 ( http://www.cvot.org ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.